Cisplatin/ Carboplatin

DRUG3 trials

Sponsors

Hansoh BioMedical R&D Company, Qilu Pharmaceutical Co., Ltd., Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Conditions

Advanced Solid TumorTriple Negative Breast Cancer Metastatic

Phase 1

ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors

RecruitingNCT06332170

Hansoh BioMedical R&D CompanyAdvanced Solid Tumor

Start: 2024-04-26End: 2028-05-30Target: 610Updated: 2024-07-18

A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors

RecruitingNCT07256782

Qilu Pharmaceutical Co., Ltd.Advanced Solid Tumor

Start: 2025-10-24End: 2028-05-31Target: 444Updated: 2025-12-01

Phase 2

Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC)

Not yet recruitingNCT07413601

Cancer Institute and Hospital, Chinese Academy of Medical SciencesTriple Negative Breast Cancer Metastatic

Start: 2026-02-10End: 2029-02-10Target: 78Updated: 2026-02-17